CN113194821B - 逆转替卡格雷活性的方法 - Google Patents

逆转替卡格雷活性的方法 Download PDF

Info

Publication number
CN113194821B
CN113194821B CN201980075991.0A CN201980075991A CN113194821B CN 113194821 B CN113194821 B CN 113194821B CN 201980075991 A CN201980075991 A CN 201980075991A CN 113194821 B CN113194821 B CN 113194821B
Authority
CN
China
Prior art keywords
seq
pharmaceutical composition
ticagrelor
hours
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980075991.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113194821A (zh
Inventor
J·李
D·J·巴兰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shunfujia 10th Pharmaceutical Co ltd
Original Assignee
Shunfujia 10th Pharmaceutical Co ltd
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69887913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113194821(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shunfujia 10th Pharmaceutical Co ltd, Phasebio Pharmaceuticals Inc filed Critical Shunfujia 10th Pharmaceutical Co ltd
Publication of CN113194821A publication Critical patent/CN113194821A/zh
Application granted granted Critical
Publication of CN113194821B publication Critical patent/CN113194821B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980075991.0A 2018-09-20 2019-09-20 逆转替卡格雷活性的方法 Active CN113194821B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733892P 2018-09-20 2018-09-20
US62/733892 2018-09-20
US201962806225P 2019-02-15 2019-02-15
US62/806225 2019-02-15
US201962836373P 2019-04-19 2019-04-19
US62/836373 2019-04-19
PCT/US2019/052173 WO2020061465A1 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Publications (2)

Publication Number Publication Date
CN113194821A CN113194821A (zh) 2021-07-30
CN113194821B true CN113194821B (zh) 2025-07-04

Family

ID=69887913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980075991.0A Active CN113194821B (zh) 2018-09-20 2019-09-20 逆转替卡格雷活性的方法

Country Status (13)

Country Link
US (1) US20210347915A1 (https=)
EP (2) EP4653465A3 (https=)
JP (2) JP7478975B2 (https=)
KR (2) KR20250161038A (https=)
CN (1) CN113194821B (https=)
AU (1) AU2019342755B2 (https=)
CA (1) CA3113654A1 (https=)
DK (1) DK3852617T3 (https=)
ES (1) ES3042247T3 (https=)
FI (1) FI3852617T3 (https=)
MX (1) MX2021003298A (https=)
PL (1) PL3852617T3 (https=)
WO (1) WO2020061465A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru
EP4337253A4 (en) * 2021-05-10 2025-03-19 Sfj Pharmaceuticals X, Ltd. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
KR102952285B1 (ko) 2021-07-13 2026-04-13 주식회사 엘지에너지솔루션 전지의 용접 상태 검사 방법
US20260022197A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
MX2013014035A (es) * 2011-06-01 2014-01-23 Astrazeneca Ab Nuevo co-cristal ticagrelor.
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
KR20220041957A (ko) * 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
KR101916956B1 (ko) * 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies

Also Published As

Publication number Publication date
ES3042247T3 (en) 2025-11-19
US20210347915A1 (en) 2021-11-11
WO2020061465A1 (en) 2020-03-26
EP3852617A1 (en) 2021-07-28
KR20210091698A (ko) 2021-07-22
CA3113654A1 (en) 2020-03-26
JP2024096134A (ja) 2024-07-12
EP3852617B1 (en) 2025-09-10
KR20250161038A (ko) 2025-11-14
AU2019342755A1 (en) 2021-05-06
DK3852617T3 (da) 2025-10-20
EP4653465A2 (en) 2025-11-26
JP2022501368A (ja) 2022-01-06
JP7478975B2 (ja) 2024-05-08
MX2021003298A (es) 2021-08-11
KR102880762B1 (ko) 2025-11-03
EP4653465A3 (en) 2026-01-07
EP3852617A4 (en) 2022-08-24
FI3852617T3 (fi) 2025-10-21
PL3852617T3 (pl) 2026-01-26
CN113194821A (zh) 2021-07-30
AU2019342755B2 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
CN113194821B (zh) 逆转替卡格雷活性的方法
JP2014077005A (ja) 抗血小板療法中の血小板抑制のメンテナンス
TW202045537A (zh) 化膿性汗腺炎的治療
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
JP2025148495A (ja) Ｂ因子阻害剤の使用方法
US20230192895A1 (en) Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
AU2017355613B2 (en) Treatment regimens
JP7842164B2 (ja) 治療用抗体製剤
US20200055942A1 (en) Treatment regimens
JPWO2020061465A5 (https=)
US20260022197A1 (en) Methods of reversing ticagrelor activity
WO2019236590A1 (en) Methods for preventing acute kidney injury
KR20260018890A (ko) 판상 건선을 치료하기 위한 방법 및 조성물
JPWO2021127525A5 (https=)
CA3142011A1 (en) Use of an anti-p-selectin antibody
EA050545B1 (ru) Терапевтические составы антитела
Musgrave DOAC Reversal Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Shunfujia 10th Pharmaceutical Co.,Ltd.

Address before: Cayman Islands, Grand Cayman

Applicant before: Shunfujia 10th Pharmaceutical Co.,Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20231030

Address after: Cayman Islands, Grand Cayman

Applicant after: Shunfujia 10th Pharmaceutical Co.,Ltd.

Address before: Pennsylvania, America

Applicant before: PHASEBIO PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant